TY - JOUR
T1 - Increased leukotriene E4 excretion in systemic mastocytosis
AU - Butterfield, Joseph H.
N1 - Funding Information:
Mayo Foundation small grant award.
Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2010/6
Y1 - 2010/6
N2 - Cysteinyl leukotrienes such as LTE4 are produced by mast cells, neutrophils, eosinophils, and macrophages. LTE4 levels have not been reported in systemic mastocytosis, a disorder with a large increase in mast cell numbers. Urinary LTE4 from patients referred for symptoms potentially due to mast cell degranulation or systemic mastocytosis was measured by a commercial cysteinyl leukotriene enzyme immunoassay kit. The diagnosis of systemic mastocytosis was established using current World Health Organization criteria. Compared with a control group of patients with various potential mast cell-related symptoms (e.g., "spells"), patients with systemic mastocytosis had a significant (P = .01) increase in urinary LTE4 excretion, whether expressed as LTE4 ng/g creatinine or as LTE4 ng/24 h. There was a moderate correlation of LTE4 ng/24 h with excretion of N-methyl histamine and serum tryptase but not with urinary 11β-prostaglandin F2α (11β-PGF2α) excretion. LTE4 excretion is increased in patients with systemic mastocytosis and potentially contributes to clinical symptoms.
AB - Cysteinyl leukotrienes such as LTE4 are produced by mast cells, neutrophils, eosinophils, and macrophages. LTE4 levels have not been reported in systemic mastocytosis, a disorder with a large increase in mast cell numbers. Urinary LTE4 from patients referred for symptoms potentially due to mast cell degranulation or systemic mastocytosis was measured by a commercial cysteinyl leukotriene enzyme immunoassay kit. The diagnosis of systemic mastocytosis was established using current World Health Organization criteria. Compared with a control group of patients with various potential mast cell-related symptoms (e.g., "spells"), patients with systemic mastocytosis had a significant (P = .01) increase in urinary LTE4 excretion, whether expressed as LTE4 ng/g creatinine or as LTE4 ng/24 h. There was a moderate correlation of LTE4 ng/24 h with excretion of N-methyl histamine and serum tryptase but not with urinary 11β-prostaglandin F2α (11β-PGF2α) excretion. LTE4 excretion is increased in patients with systemic mastocytosis and potentially contributes to clinical symptoms.
KW - Leukotriene E
KW - Mast cells
KW - Systemic mastocytosis
UR - http://www.scopus.com/inward/record.url?scp=77952111914&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952111914&partnerID=8YFLogxK
U2 - 10.1016/j.prostaglandins.2010.03.003
DO - 10.1016/j.prostaglandins.2010.03.003
M3 - Article
C2 - 20380889
AN - SCOPUS:77952111914
SN - 1098-8823
VL - 92
SP - 73
EP - 76
JO - Prostaglandins and Other Lipid Mediators
JF - Prostaglandins and Other Lipid Mediators
IS - 1-4
ER -